2013 Annual Meeting | S58 - Peripheral Neuropathy II
| 02:00 PM - 03:30 PM | Abstract |
001 - Treatment Induced Neuropathy of Diabetes
Christopher H. Gibbons, MD, FAAN |
| 02:00 PM - 03:30 PM | Abstract |
002 - Analgesic Efficacy of Fulranumab in Patients with Painful Diabetic Peripheral Neuropathy in a Randomized, Placebo-Controlled, Double-Blind Study
|
| 02:00 PM - 03:30 PM | Abstract |
003 - A Population Based Assessment of Polyneuropathy and Associated Disability
E. M. Hoffman, DO, PhD |
| 02:00 PM - 03:30 PM | Abstract |
004 - Domino Liver Transplantation (DLT) and De Novo Familial Amyloid Polyneuropathy (FAP): The Portuguese Experience
|
| 02:00 PM - 03:30 PM | Abstract |
005 - Long-Term Use of Tafamidis in Transthyretin Familial Amyloid Polyneuropathy: A Single Center Experience
Teresa Coelho, MD |
| 02:00 PM - 03:30 PM | Abstract |
006 - The Clinical Spectrum of Anti-MAG Neuropathies at the National Hospital for Neurology
|
| Jun Li, MD, PhD, FAAN | The institution of Dr. Li has received personal compensation in the range of $500-$4,999 for serving as a Consultant for FDA. The institution of Dr. Li has received research support from NIH. Dr. Li has a non-compensated relationship as a Associate Editor of ACTN journal with ANA that is relevant to AAN interests or activities. |
| Michael J. Polydefkis, MD, FAAN | Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharmaceutical . Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. |
| Christopher J. Klein, MD, FAAN | Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sangamo Therapeutics . Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma. |
| E. M. Hoffman, DO, PhD | Dr. Hoffman has nothing to disclose. |
| Luis F. Maia | No disclosure on file |
| Ana M. Silva, MD | No disclosure on file |
| Nathan P. Staff, MD, PhD, FAAN | Dr. Staff has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stem Cell Research & Therapy. Dr. Staff has received research support from National Institutes of Health. |
| Teresa Coelho, MD | Dr. Coelho has nothing to disclose. |
| Michael P. Lunn, MBBS | No disclosure on file |
| Aaron Ellenbogen, DO | Dr. Ellenbogen has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for allergan. Dr. Ellenbogen has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for allergan. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for ipsen. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda. |
| Hadi Manji | No disclosure on file |
| Christopher H. Gibbons, MD, FAAN | Dr. Gibbons has received personal compensation for serving as an employee of CND Life Sciences. Dr. Gibbons has stock in CND Life Sciences. Dr. Gibbons has received publishing royalties from a publication relating to health care. Dr. Gibbons has received personal compensation in the range of $5,000-$9,999 for serving as a Expert Advisor with Department of Justice. |
| No disclosure on file | |
| Roy L. Freeman, MD | Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. |
| Douglas R. Jeffery, MD, PhD | No disclosure on file |
| Mary Reilly, MD, FRCP, FRCPI | The institution of Mary Reilly, MD, FRCP, FRCPI has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alynlam. Mary Reilly, MD, FRCP, FRCPI has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AKCEA. Mary Reilly, MD, FRCP, FRCPI has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inflectis. The institution of Mary Reilly, MD, FRCP, FRCPI has received research support from MRC. The institution of Mary Reilly, MD, FRCP, FRCPI has received research support from NIH. The institution of Mary Reilly, MD, FRCP, FRCPI has received research support from MDA. |
| Orla Hardiman, MD, FRCPI, FAAN | Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Pharmaceuticals. Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cytokinetics . Dr. Hardiman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hardiman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Taylor and Francis. The institution of Dr. Hardiman has received research support from Science Foundation Ireland. The institution of Dr. Hardiman has received research support from HRB. |
| John Thipphawong, MD | No disclosure on file |
| Gregory Rosas, PhD | No disclosure on file |
| Elizabeth Nowak | No disclosure on file |
| Martin E. Sanders, MD | No disclosure on file |